GIP and Hyperglycemia: Pasireotide also decreases secretion of the incretin hormones GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) without altering hepatic or peripheral insulin sensitivity, rendering antihyperglycemic drugs with incretin-based mechanism of action interesting candidates justified by pathophysiology for the treatment of pasireotide-associated hyperglycemia or diabetes (20, 21).